iGii and Prymexa to partner on menopause diagnosis toolkit
Multi-million pound deal agreed
Scottish-based sensor technology start-up iGii and health monitoring company Prymexa have agreed a multi-million-pound deal to diagnose early signs of menopause with an at-home toolkit.
Early identification of perimenopause allows for more personalised advice, treatment and support from medical professionals. Yet currently 60% of women under 40 do not feeling informed about perimenopause or menopause, many experience a range of symptoms and increased risks of depression, osteoporosis and cardiovascular disease without guidance on managing these. A lack of awareness and monitoring can lead to misdiagnosis and missed opportunities for early intervention.
The iGii / Prymexa toolkit will look at various monitoring options, including wearable devices and sensors, to enable simple and affordable at-home monitoring that can be closely tracked by a medical professional.
Integral to the toolkit will be iGii’s technology - a sustainable carbon nanomaterial ‘Gii’, which provides a low-cost, eco-friendly, and highly sensitive alternative to traditional carbon and metal-based sensors, making it particularly effective for accurate assessment of menopause symptoms.
Sara Pardoe, Chief Executive Officer, Prymexa, said:
“Menopause receives a fraction of the investment compared to other medical fields, yet half the population will experience it and demand for effective management solutions is growing exponentially. Our research aims to bring individuals closer to a simple, clear understanding of their menopause journey and how to best manage it.”
So far Prymexa has created two types of smart wearable for its toolkit, as well as an app for tracking health data and a clinicians portal. The start-up has also launched Moona Health, a support community for perimenopause and menopause. Partnering with iGii is the ‘last piece of the puzzle’ to complete the toolkit.
Jean-Christophe Granier, CEO, iGii, said:
“Gii has the potential to significantly improve point-of-care human diagnostics and make accurate, quick medical results the norm. Its properties provide a more affordable, sustainable, scalable and sensitive sensing platform for high-quality results in labs and at home. This project with Prymexa highlights the real value and potential of Gii and we look forward to working with them to positively impact the lives of those going through the perimenopause period.”
Beyond perimenopause and menopause, iGii and Prymexa will also evolve their work and apply their technology into many other areas where chronic disease is prevalent. The ambition is to support the ‘waiting well’, those on waiting lists and even those who are in Emergency Departments waiting to be seen.